NDA 209112 · Mcguff
Ascor
Ascorbic Acid · Intravenous · Vitamin C
OrphanLast checked: Nov 19, 2026Latest source record: Jan 17, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Oct 2, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
617
128 Phase 3, 49 recruiting
FAERS reports
23,363
16,695 serious, 2,648 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 29, 2026.
1. INDICATIONS AND USAGE ASCOR is vitamin C indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. Limitations of Use ASCOR is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy. ASCOR is vitamin C indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. Limitations of Use ASCOR is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 2, 2017 Original approval · Type 7 - Drug Already Marketed without Approved NDA OrphanLabelLetterReview
1 products under this application
- ASCOR · ASCORBIC ACID 25,000MG/50ML (500MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ascorbic Acid" as an intervention, any sponsor and status, largest first.
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04353180 · 100,000 participants (planned) · Start Aug 2021 · Primary completion Oct 2021
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment; Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment and 3 more · For: COVID19
Sites: Cairo, Egypt · 2 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)Pivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT00135707 · 10,154 participants · Start Jun 2003 · Primary completion Oct 2008
Drug: Dietary Supplement/Vitamins; Placebo for Vitamin C and Vitamin E · For: Preeclampsia
Sites: Birmingham, Alabama; Chicago, Illinois; Detroit, Michigan · 16 sites in all
- A Preventive Treatment for Migrant Workers at High-risk of COVID-19Pivotal-lookingCompleted
National University Hospital, SingaporeAcademic, hospital or other
NCT04446104 · 4,257 participants · Start May 13, 2020 · Primary completion Aug 31, 2020
Drug: Hydroxychloroquine Sulfate Tablets; Ivermectin 3mg Tab and 2 more · For: Covid-19
Sites: Singapore, Singapore
- Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)Pivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00064753 · 4,110 participants · Start May 2002 · Primary completion Oct 2011
Drug: High Dose Multivitamin · For: Chronic Kidney Disease; Cardiovascular Disease; Death
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 30 sites in all
- A Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong ProvincePivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00339768 · 3,411 participants · Start Jul 1, 1995 · Primary completion Jun 10, 1996
Drug: Amoxicillin/omeprazole · For: Precancerous Gastric Lesions
Sites: Beijing, China
- Perioperative Vitamin C to Reduce Persistent Pain After Total Knee ArthroplastyPivotal-lookingRecruiting
University Health Network, TorontoAcademic, hospital or other
NCT06123715 · 3,216 participants (planned) · Start Apr 16, 2024 · Primary completion Dec 31, 2029
Drug: Vitamin C; Placebo · For: Chronic Pain; Knee Pain Chronic; Post Operative Pain and 1 more
Sites: Toronto, Canada · 3 sites in all
- A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth DiseasePivotal-lookingCompleted
The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineAcademic, hospital or other
NCT01182532 · 3,000 participants · Start May 2010 · Primary completion Oct 2011
Drug: TCM Syndrome Differentiation and Treatment · For: Hand, Foot and Mouth Disease
Sites: Hefei, China; Beijing, China; Chongqing, China · 21 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue2,366
- pain2,120
- nausea2,025
- diarrhoea1,860
- headache1,830
- drug ineffective1,800
- dyspnoea1,711
- off label use1,601
- vomiting1,585
- asthenia1,491
- rash1,425
- dizziness1,363
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 369 |
| 2005 | 810 |
| 2006 | 875 |
| 2007 | 890 |
| 2008 | 1,126 |
| 2009 | 1,295 |
| 2010 | 1,093 |
| 2011 | 1,802 |
| 2012 | 1,842 |
| 2013 | 428 |
| 2014 | 485 |
| 2015 | 493 |
| 2016 | 661 |
| 2017 | 794 |
| 2018 | 1,056 |
| 2019 | 1,037 |
| 2020 | 1,325 |
| 2021 | 1,279 |
| 2022 | 1,328 |
| 2023 | 1,222 |
| 2024 | 1,306 |
| 2025 | 1,093 |
| 2026 | 753 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vitamin C for preventing and treating the common cold.
Hemilä H, Chalker E · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Randomized trial of topical ascorbic acid in DMSO versus imiquimod for the treatment of basal cell carcinoma.
Burke B, Bailie JE · Biomed Pharmacother 2022 · Randomized Controlled Trial
- Microneedling as an adjuvant to topical therapies for melasma: A systematic review and meta-analysis.
Bailey AJM, Li HO, Tan MG, et al. · J Am Acad Dermatol 2022 · Meta-Analysis, Systematic Review
- Mortality in septic patients treated with vitamin C: a systematic meta-analysis.
Scholz SS, Borgstedt R, Ebeling N, et al. · Crit Care 2021 · Meta-Analysis, Systematic Review
- Bleeding tendency and ascorbic acid requirements: systematic review and meta-analysis of clinical trials.
Hujoel PP, Kato T, Hujoel IA, et al. · Nutr Rev 2021 · Meta-Analysis, Systematic Review
- Efficacy of vitamin C supplementation in preventing and treating complex regional pain syndrome type I (CRPS-I) in Orthopedic patients: A systematic review and meta-analysis.
Ranjbar Moghaddam M, Nasiri-Formi E, Merajikhah A · Int J Orthop Trauma Nurs 2024 · Systematic Review, Meta-Analysis
Sponsor: Mcguff
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.